International Journal of STD & AIDS最新文献

{"title":"A systematic review of Human T-cell Lymphotropic Virus type-1 (HTLV-1) seroprevalence worldwide and an update on HTLV-1 diagnoses and associated diseases in England and Wales.","authors":"Salyha Mughal, Jennifer Tosswill, Carolina Rosadas, Katy Davison, Nick Andrews, Graham P Taylor, Daniel Bradshaw","doi":"10.1177/09564624261486905","DOIUrl":"https://doi.org/10.1177/09564624261486905","url":null,"abstract":"<p><p>BackgroundHuman T-cell lymphotropic virus type-1 (HTLV-1) is a retrovirus, mainly transmitted sexually, which causes adult T-cell leukaemia/lymphoma (ATLL) and HTLV-1 associated myelopathy (HAM). We aimed to update global HTLV-1 seroprevalence estimates, estimate the number of people living with HTLV-1 (PLHTLV) in England and Wales (E&W), and present E&W HTLV-1 surveillance data.MethodWe systematically reviewed countries with new HTLV-1 prevalence data since the 2015 European Centres for Disease Control report, including studies of adults in the general population, pregnant women and blood donors (Ovid MEDLINE, 01/09/2014-17/02/2023). Global seroprevalence and UK census data were used to estimate the number of PLHTLV in E&W for 1991 and 2021. Reference laboratory and hospital data were combined to describe patterns in new HTLV-1 diagnoses, and associated diseases, in 2013-2022, in E&W. Diagnoses in 2013-2022 were compared with 1993-1997 using Incidence Rate Ratios (IRR).ResultsNew seroprevalence data were found for Pakistan (0.19%, blood donors), Malawi (0.96%, healthy mothers), Jordan (0.00%, blood donors), Vietnam (0.00%, blood donors) and New Caledonia (0.60%, general population); 4/5 studies had a high risk of bias. Among 749 newly-diagnosed PLHTLV in E&W (2013-2022), most were women (58%, 434/749) and tested in London (64%, 480/749). Where recorded, Black Caribbean ethnicity predominated (61%, 228/373); 51% (396/619) were symptomatic, most commonly with ATLL (47%, 187/396). Comparing 1993-1997 with 2013-2022, the IRR was 1.26 (95%CI 1.09-1.46) overall, 1.60 (95%CI 1.17-2.23) for ATLL and 0.35 (95%CI 0.23-0.51) for HAM. Assuming all cases were due to migration from endemic countries, the estimated number of PLHTLV in E&W increased from 11,654 (range 3,804-19,504) in 1991 to 28,846 (range 10,365-47,328) in 2021.ConclusionsIn E&W, rising annual ATLL diagnoses are consistent with an increase in the estimate of the number of PLHTLV, necessitating enhanced public health interventions. The reduced IRR for HAM requires further investigation.</p>","PeriodicalId":14408,"journal":{"name":"International Journal of STD & AIDS","volume":" ","pages":"9564624261486905"},"PeriodicalIF":1.6,"publicationDate":"2026-09-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148919770","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Attitudes, knowledge, facilitators, and barriers to doxycycline post-exposure prophylaxis for sexually transmitted infections among gay and bisexual men who have sex with men and trans-gender women: A mixed-methods scoping review.","authors":"Fergal Fouhy, George Budden, Erica Pool, Manik Kohli","doi":"10.1177/09564624261485006","DOIUrl":"https://doi.org/10.1177/09564624261485006","url":null,"abstract":"<p><p>BackgroundAs doxycycline post-exposure prophylaxis (doxyPEP) implementation for bacterial STI prevention expands among gay, bisexual and other men who have sex with men (GBMSM) and transgender women (TGW), this scoping review synthesised community knowledge, attitudes, barriers, facilitators and practices to inform guidelines and support uptake.MethodsThis scoping review followed JBI methodology and was reported per PRISMA-ScR. Three databases (Embase, Medline/PubMed, Web of Science) were searched for articles on community perspectives of doxyPEP among GBMSM and TGW published from 2013 to 2025. Included studies were screened, data extracted using inductive coding, and analysed thematically. Factors were mapped onto the Knowledge, Attitudes, and Practices (KAP) Model.Results24 studies (18,428 participants) met inclusion criteria, (North America (n = 12), Europe (n = 6), Asia (n = 3), Oceania (n = 3)). Most were quantitative (n = 20), with two qualitative and two mixed-methods studies, recruiting primarily via online/app-based surveys or from sexual health clinics. Five coding categories emerged: awareness and knowledge; previous use; willingness to try; barriers and concerns; and facilitators and predictors. Awareness and prior use were low and heterogenous (ranging from 17 to 67%), yet willingness was moderate to high (12% to 90%), particularly after brief education and when free of charge. Prior use remained limited (2.5-36%). Predictors of interest included prior STI diagnosis, HIV PrEP use, living with HIV, multiple sexual partners, condomless sex, and higher educational attainment. Side effects and antimicrobial resistance (AMR) were the primary concerns.ConclusionsClinicians and sexual health services should prioritise opportunistic doxyPEP offers to those with recent STIs, HIV PrEP use, or HIV, embedding education and low/no-cost access within routine care to close the awareness-uptake gap. Public health bodies should invest in robust AMR surveillance alongside implementation, and community-based education should directly address side-effect concerns. Extending research and delivery models to under-represented groups is also needed to ensure equitable, evidence-based uptake.</p>","PeriodicalId":14408,"journal":{"name":"International Journal of STD & AIDS","volume":" ","pages":"9564624261485006"},"PeriodicalIF":1.6,"publicationDate":"2026-09-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148919782","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Anorectal lymphogranuloma venereum (LGV) circulation dynamics in Buenos Aires: Nine-year surveillance and therapeutic implications.","authors":"Laura Svidler López, Lucas Matías Tomatis, Joseph Carlos Torres Guerrero, Deysi López Aquino, Luciana La Rosa, Karina Andrea Büttner, María Lucía Gallo Vaulet, Andrea Carolina Entrocassi, Marcelo Rodríguez Fermepin","doi":"10.1177/09564624261486772","DOIUrl":"https://doi.org/10.1177/09564624261486772","url":null,"abstract":"<p><p>BackgroundLymphogranuloma venereum (LGV), caused by <i>Chlamydia trachomatis</i> L-genotypes, has re-emerged as a major anorectal infection in men who have sex with men (MSM), especially in people living with HIV. Distinguishing LGV from non-LGV <i>C. trachomatis</i> is essential because LGV requires 3 weeks of doxycycline. Long-term Latin American data are lacking.MethodsAnorectal swabs from patients with suspected anorectal sexually transmitted infections were studied in a cross-sectional study conducted at two Buenos Aires coloproctology referral centers (August 2017-November 2025). Anorectal swabs were tested for <i>C. trachomatis</i> by NAAT and positive samples were genotyped by PCR-RFLP targeting <i>ompA</i>. Monthly LGV positivity was analyzed using the modified Farrington algorithm to detect epidemic peaks and seasonality, with sensitivity analysis excluding months with <7 samples.ResultsOf 700 anorectal swabs, 285 (41%) were <i>C. trachomatis</i> positive. Among public-hospital samples with conclusive genotyping, 148/179 (83%) were LGV; in the private center, 78 additional LGV cases were confirmed, totaling 226 LGV cases. HIV coinfection was 78% in LGV versus 100% in non-LGV cases (<i>p</i> = 0.0016). Concurrent <i>T. pallidum</i> or <i>N. gonorrhoeae</i> infection occurred in 25% of cases and was associated with LGV. The endemic baseline was approximately 32% (range 28-36%), with no seasonal pattern or trend. Pandemic-era epidemic alarms disappeared after excluding low-volume months.ConclusionsAnorectal LGV is endemic in Buenos Aires, with no seasonality, and a ∼32% pre-test probability among symptomatic patients at specialized clinics. This supports considering empirical 3-week doxycycline for MSM with rectal symptoms and <i>C. trachomatis</i> infection when genotyping is unavailable, until further trials confirm the non-inferiority of proposed shortened regimens. Biovar-specific testing remains the goal for targeted therapy.</p>","PeriodicalId":14408,"journal":{"name":"International Journal of STD & AIDS","volume":" ","pages":"9564624261486772"},"PeriodicalIF":1.6,"publicationDate":"2026-09-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148911701","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Forty years after the first case: The uneven geography of India's HIV success.","authors":"Bejo Jacob Raju, Sachu R Sunny","doi":"10.1177/09564624261487929","DOIUrl":"https://doi.org/10.1177/09564624261487929","url":null,"abstract":"<p><p>BackgroundAs India marks four decades since its first identified HIV case, national indicators tell a story of remarkable success: prevalence, incidence and HIV-related mortality have fallen since the peak of the epidemic. Yet this aggregate picture obscures a quieter and more troubling shift - the epidemic that the National AIDS Control Programme was built to fight is not the epidemic it now faces.Key concernsThe residual burden increasingly reveals populations, places and gaps in care that national figures can mask: pregnant and breastfeeding women who acquire HIV after an initial negative antenatal test, States recording rising mortality despite substantial national declines, and people reaching antiretroviral therapy centres only after advanced immunosuppression. Drawing on the Technical Report released by the Government of India (2024) on HIV estimation and recent peer-reviewed evidence, this opinion piece argues that India's HIV response risks mistaking a slowing epidemic for a defeated one.ConclusionFour decades after the first identified case, India's next HIV response must be built around the epidemic it faces today, not the one that shaped the architecture of the national HIV programme in 1992.</p>","PeriodicalId":14408,"journal":{"name":"International Journal of STD & AIDS","volume":" ","pages":"9564624261487929"},"PeriodicalIF":1.6,"publicationDate":"2026-09-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148906168","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Exploratory survey to assess interest in herpes simplex virus pre- and post-exposure prophylaxis.","authors":"Justin Lorence Wang, Robert John Raad, Jeremy Joseph Rosenbaum, Conor Mathew Tierney, Michael P Dubé, Saahir Khan","doi":"10.1177/09564624261486080","DOIUrl":"https://doi.org/10.1177/09564624261486080","url":null,"abstract":"<p><p>BackgroundHerpes simplex virus (HSV) remains one of the most prevalent sexually transmitted infections worldwide, yet no established pharmacologic pre- or post-exposure prophylaxis strategy currently exists for primary HSV prevention. This study evaluated patient interest in HSV pre-exposure prophylaxis (PrEP) and post-exposure prophylaxis (PEP) to inform future clinical trial feasibility.MethodsAn anonymous cross-sectional online survey was conducted from August 2025 to April 2026 through outpatient clinics affiliated with an academic medical center, county hospital, and a community-based HIV/STI organization in Los Angeles, California. Participants were also encouraged to share a public survey link to facilitate broader dissemination. Participants were asked about demographics, sexual practices, STI prevention behaviors, and interest in hypothetical HSV PrEP and HSV PEP strategies.ResultsThere were 89 completed quality controlled surveys suitable for analysis. Participants had a median age of 30 years (range 21-76), and the majority identified as cisgender male (65%), white (65%), and HIV-negative (96%). Interest in HSV PEP (75%) exceeded HSV PrEP (54%) across all analyzed groups. Participants currently taking HIV PrEP demonstrated particularly high interest in both HSV PrEP (76%) and HSV PEP (82%). Common barriers included daily medication burden and concerns regarding side effects.ConclusionsInterest in HSV prophylaxis was observed, particularly among individuals already engaged in STI prevention strategies. These findings support the feasibility of future clinical trials evaluating HSV prophylaxis in high-risk populations.</p>","PeriodicalId":14408,"journal":{"name":"International Journal of STD & AIDS","volume":" ","pages":"9564624261486080"},"PeriodicalIF":1.6,"publicationDate":"2026-09-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148880364","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Challenges to sustained HIV care engagement after ED Re-linkage: The influence of substance use disorders.","authors":"Haley Haines, Richard Rothman, Bhakti Hansoti, Nyah Johnson, Mun Heol Cho, Dante Brown, David Rudolph, Genevieve Barrow, Adena Greenbaum, Joyce Jones, Kaye Park, Mustapha Saheed, Yu-Hsiang Hsieh, Gaby Dashler","doi":"10.1177/09564624261483246","DOIUrl":"https://doi.org/10.1177/09564624261483246","url":null,"abstract":"<p><p><b>Background:</b> Emergency department (ED)-based HIV linkage-to-care programs effectively connect newly diagnosed people living with HIV (PLWH) to care and can also facilitate re-engagement among patients disengaged from HIV care. The linkage-to-care needs of these populations may differ substantially. We sought to identify factors associated with engagement outcomes following ED-based re-linkage to inform service delivery. <b>Methods:</b> This cross-sectional analysis used programmatic data from an ED-based HIV linkage-to-care program that served PLWH identified by automated electronic health record alerts to program staff upon ED presentation from January 2023 to July 2024. Patients were classified as not engaged in HIV care if, within the preceding three months, they had missed at least one HIV care appointment without rescheduling and had not refilled their antiretroviral therapy (ART). These individuals were approached at the bedside and offered re-linkage-to-care services. Among patients who received re-linkage-to-care services, the primary outcome was attendance at the scheduled HIV care appointment. ART refill within three months of the scheduled appointment was assessed descriptively. Associations between sociodemographic and clinical characteristics and appointment nonattendance were evaluated using univariate and multivariable logistic regression models. <b>Results:</b> Among 892 PLWH presenting to the ED, 113 (13%) were classified as not engaged in HIV care, of whom 66 (58%) received re-linkage-to-care services. All 66 patients who received re-linkage-to-care services had an HIV care appointment scheduled, and 40 (61%) attended their scheduled appointment. In adjusted analyses, patients with a history of substance use disorder had greater odds of appointment non-attendance (aOR=4.50, 95% CI 1.57-14.88; <i>p</i> = 0.03). All patients who attended subsequently refilled ART. <b>Conclusions:</b> A history of substance use disorder was associated with greater odds of HIV care appointment nonattendance following ED-based re-linkage-to-care services, highlighting the need for tailored substance use disorder informed strategies that address social, behavioral, and structural barriers to sustained HIV care engagement.</p>","PeriodicalId":14408,"journal":{"name":"International Journal of STD & AIDS","volume":" ","pages":"9564624261483246"},"PeriodicalIF":1.6,"publicationDate":"2026-09-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148886926","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Anti-IL-17 therapy in people living with HIV who have cutaneous psoriasis: A four-patient case series.","authors":"Melike Merve Güçlü, Fatma Aslı Hapa, Fatma Elif Yıldırım","doi":"10.1177/09564624261485266","DOIUrl":"https://doi.org/10.1177/09564624261485266","url":null,"abstract":"<p><p>AimTo describe the clinical, immunological, virological and safety outcomes observed during anti-IL-17 therapy in patients living with HIV who had cutaneous psoriasis.MethodFour patients living with HIV who had cutaneous psoriasis and were treated with anti-IL-17 agents were included in this case series. Psoriasis Area Severity Index (PASI) scores, CD4 cell counts, HIV RNA levels, treatment duration and adverse events were obtained from medical records.ResultsThree patients received secukinumab and one received ixekizumab. Psoriasis improved in all four patients. CD4 cell counts remained stable or increased, while HIV RNA levels remained suppressed or declined following antiretroviral therapy. No adverse events were observed during follow-up.ConclusionAnti-IL-17 therapy was associated with clinical improvement without observed deterioration in immunological or virological parameters in this small case series. Larger prospective studies are required before conclusions regarding safety can be drawn.</p>","PeriodicalId":14408,"journal":{"name":"International Journal of STD & AIDS","volume":" ","pages":"9564624261485266"},"PeriodicalIF":1.6,"publicationDate":"2026-09-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148880369","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A precautionary tale of lenacapavir drug-drug interactions: A case series of two persons living with HIV receiving long-acting injections.","authors":"Patricia Pecora Fulco, Elizabeth Winthrop, Gonzalo M Bearman","doi":"10.1177/09564624261461789","DOIUrl":"10.1177/09564624261461789","url":null,"abstract":"<p><p>Lenacapavir is now approved for highly treatment experienced persons living with HIV (PLWH) and for HIV pre-exposure prophylaxis (PrEP). Limited lenacapavir clinical data exist with real-world drug-drug interactions. We report two possible drug-drug interactions with ambulatory lenacapavir subcutaneous injections in two PLWH prescribed long-acting injection therapy. Case 1 describes a PLWH prescribed clopidogrel after an acute cerebrovascular event receiving an antiretroviral (ARV) regimen including subcutaneous lenacapavir and ibalizumab biweekly infusions. The clopidogrel was discontinued with no harm noted. Case 2 is a highly treatment experienced PLWH prescribed an ARV regimen including subcutaneous lenacapavir and intramuscular cabotegravir/rilpivirine injections on concomitant inhaled and nasal fluticasone. Symptoms consistent with adrenal insufficiency were reported with immediate fluticasone discontinuation and transition to beclomethasone. The patient's baseline cortisol concentration was low with improvement after fluticasone discontinuation. The electronic medical record alerts were customized to note these possible lenacapavir drug-drug interactions, similar to protease inhibitors/pharmacokinetic boosters (ritonavir and cobicistat) to prevent future events. This case series highlights possible lenacapavir drug-drug interactions and is a precautionary tale to other institutions to consider customizing electronic medical alerts for this novel long-acting injection.</p>","PeriodicalId":14408,"journal":{"name":"International Journal of STD & AIDS","volume":" ","pages":"1115-1120"},"PeriodicalIF":1.6,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148271577","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Determinants and psychosocial correlates of incomplete partner notification following sexually transmitted infection diagnosis: A cross-sectional study from central India.","authors":"Rudraksh Kesharwani, Chhavi Singodia","doi":"10.1177/09564624261472701","DOIUrl":"10.1177/09564624261472701","url":null,"abstract":"","PeriodicalId":14408,"journal":{"name":"International Journal of STD & AIDS","volume":" ","pages":"1111-1114"},"PeriodicalIF":1.6,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148603231","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Lung cancer screening among people with HIV, 2018-2023.","authors":"Subhashini A Sellers, Lindsay E Browne, Heather I Henderson, Amanda E Moy, Deana M Agil, Amy Durr, Claire E Farel, Joseph J Eron, Sonia Napravnik","doi":"10.1177/09564624261469254","DOIUrl":"10.1177/09564624261469254","url":null,"abstract":"<p><p>BackgroundLung cancer is the leading cause of cancer-related death among persons with HIV (PWH) in the United States. Annual screening with low-dose chest computed tomography may reduce mortality, but uptake remains unclear. We sought to characterize lung cancer screening eligibility and uptake among PWH engaged in HIV care at a Southeastern tertiary care center.MethodsA cross-sectional analysis with 6 time points corresponding to each calendar year from 2018 through 2023 among PWH receiving care. Data were collected from electronic health records, clinical event adjudications, and patient-reported outcomes. Prevalence differences and 95% CIs were estimated across demographic and clinical characteristics.ResultsAmong 2798 PWH in care, 74% were men, 57% identified as non-Hispanic Black and the median age was 48 years (IQR: 35-57). Among all PWH, 62% had a history of smoking with a median pack-year history of 40 (IQR: 27-50) and 51% of these were current smokers. The proportion of PWH meeting United States Preventative Services Task Force screening criteria increased from 6% in 2018 to 15% by 2023 (<i>p</i> < 0.05). Overall, 13% of PWH were eligible for screening, among whom less than one-third (27%) received screening at least once during follow-up. Annual screening was 11% and 24% in 2018 and 2023, respectively, (<i>p</i> = 0.10).ConclusionsLung cancer screening utilization remains low, even among a high-risk population in the Southeastern United States. Understanding barriers to screening is needed to improve lung cancer outcomes among PWH.</p>","PeriodicalId":14408,"journal":{"name":"International Journal of STD & AIDS","volume":" ","pages":"1086-1094"},"PeriodicalIF":1.6,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13494115/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148630394","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}